Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-D: daprodustat versus recombinant human erythropoietin in dialysis patients with CKD-related anemia
NL-OMON50208Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daprodustat, epoetin alfa and darbepoetin alfa in anemia of renal disease (2 arms), sponsored by GSK. Primary endpoints: Time to first adjudicated major adverse cardiovascular event and Mean change in hemoglobin. Started Sep 2017; status: active, not recruiting.
02
Drugs
daprodustatepoetin alfadarbepoetin alfa
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on NL-OMON50208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50208.